Aclaris Therapeutics soars after promising study against rheumatoid arthritis

January 20, 2021 14:00

During the trading day yesterday, Aclaris Therapeutics’ stock shot upwards with a rise of more than 200%. It overcame the wide gap not only from its previous resistance level at $7.70 and its average of 200 periods in the weekly chart, but also saw it trading at levels unseen since July 2018, marking daily highs at $ 19.80 per share.

These strong rises are due to the fact that it announced preliminary data from its phase 2 study on rheumatoid arthritis treatment, in which the results were very promising. Clinical tests are being conducted for up to 12 weeks in both moderate and severe cases with its oral drug, ATI-450.

This biopharmaceutical company is dedicated to the development of immunoinflammatory drugs, which in recent times have been hit hard on the stock market, but that during the last 3 months they have multiplied their value by 4.

Technically speaking, yesterday's strong rises could be a good foothold for the listing of this company, given that although it cannot be ruled out that it should make a correction in the coming sessions, the announcement of this very promising study may re-launch this company.

As we mentioned before, this rise has achieved the break of 3 levels of resistance (level of 7.70, an average of 200 in red, and level of 16.06), so it is not ruled out that the price can seek some of these levels since they currently act as its main supports. Although at first, it seems that this study has managed to break the downtrend:

Source: Admiral Markets MetaTrader 5. Aclaris Therapeutics weekly chart. Data range: from October 4, 2015 to January 20, 2021. Prepared on January 20, 2021 at 11:30 CET. Keep in mind that past returns do not guarantee future returns.

Price evolution of the last 5 years:

2020: 242.32%

2019: -74.42%

2018: -70.03%

2017: -9.18%

2016: 0.74%

With an Admiral Markets Trade.MT5 account, you can trade Contracts for Difference (CFDs) on Tesla and over 3,000 stocks! CFDs allow traders to try to profit from both bull and bear markets, as well as profit from the use of leverage. Click on the following banner to open an account today:

Trade Forex & CFDs


The data provided provides additional information on all analyzes, estimates, forecasts, forecasts, market reviews, weekly outlooks or other evaluations or similar information (hereinafter "Analysis") published on the Admiral Markets website. Before making any investment decisions, pay close attention to the following:

  1. This is a marketing communication. The content is posted for informational purposes only and should not be construed as investment advice or recommendation. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and is not subject to any prohibition on pre-dissemination of investment research.
  2. Each investment decision is made by each client alone, while Admiral Markets UK Ltd (Admiral Markets) will not be liable for any loss or damage arising from such a decision, whether based on content or not.
  3. In order to protect the interests of our clients and the objectivity of the Analysis, Admiral Markets has established relevant internal procedures for the prevention and management of conflicts of interest.
  4. The analysis is prepared by an independent analyst, Roberto Rojas, SEO implementer (hereinafter "Author") based on personal estimates.
  5. While all reasonable efforts are made to ensure that all sources of content are reliable and that all information is presented, as much as possible, in an understandable, timely, accurate, and complete manner, Admiral Markets does not guarantee accuracy. or integrity of any information contained in the Analysis.
  6. Any past performance or modelling of the financial instruments indicated in the content should not be construed as an express or implied promise, guarantee, or implication of Admiral Markets for any future performance. The value of the financial instrument may rise and fall, and the preservation of the asset's value is not guaranteed.

7. Leveraged products (including contracts for difference) are speculative in nature and may generate profit or loss. Before you start trading, make sure you fully understand the risks.

An all-in-one solution for spending, investing, and managing your money

More than a broker, Admirals is a financial hub, offering a wide range of financial products and services. We make it possible to approach personal finance through an all-in-one solution for investing, spending, and managing money.